Jubilant Organosys announces new facility for Niacinamide and 3-Cyanopyridine

NewsGuard 100/100 Score

Jubilant Organosys Limited, an integrated pharmaceutical industry player and the largest Custom Research and Manufacturing Services Company in India, announced today that it is setting up Niacinamide and 3-Cyanopyridine plant of 10,000 TPA each, expected to be ready by end of 2010.

Jubilant is currently ranked amongst the top three manufacturers of Niacin & Niacinamide (Vitamin B3) worldwide and is the only manufacturer of Niacinamide with complete backward integration to the basic feed-stock. Jubilant is also the largest producer of Beta Picoline globally, a critical raw material for the manufacture of Vitamin B3.

Commenting on the development Mr. Pramod Yadav, CEO (Advance Intermediates & Vitamins) of Jubilant Organosys said “Our decision to set up a new facility for Niacinamide reflects our commitment to our customers and Vitamin B3 Market. Through our in-house research we have developed a very cost efficient and environmental friendly process for the manufacture of these products which will translate into value for our customers. We believe with our new capacity we will strengthen our relationship with the existing wide spread customers globally as well as develop new markets.”

Source:

Jubilant Organosys Ltd.,

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New research sheds light on how GLP-1 obesity drugs may change food cravings